<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390010</url>
  </required_header>
  <id_info>
    <org_study_id>Active management of labour</org_study_id>
    <nct_id>NCT03390010</nct_id>
  </id_info>
  <brief_title>Misoprostol Versus Active Management of Labour in CS</brief_title>
  <official_title>Intrauterine Misoprostol With Active Management of Labour Versus Active Management of Labour for Prevebtion of Postpartum Hemorage in Cesarean Section ,Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aljazeera Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aljazeera Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several treatment strategies are emplemented to prevent post delivery hemorage and decreasing
      maternal morbidity and mortality .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many approved drugs are used in prophylaxis against postpartum hemorage from these
      medications are the (syntocinon combined with methergine ) that are known as active
      management of labour drugs .

      Moreover there is misotac , that also guards against postpartum hemorage .

      All these medications act in a different way to cause uterine contraction post delivery to
      prevent uterine atony .

      -Here we are comparing the additive value of misotac intrauterine to syntocinon and
      methergine in comparison to the usually used syntocinon plus methergine .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 28, 2017</start_date>
  <completion_date type="Actual">June 6, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of participants who passed cesarean section without postpartum hemorage</measure>
    <time_frame>within 2 days post CS</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Extra medication group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-Procedure : Giving misoprostol plus syntocinon and methergibe drugs during CS
this group in which prevention of uterine atony is made by intrauterine misotac plus the usual syntocinon and methergine during cesarean section</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active management of labour group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure: Giving syntocinon and methergine drugs during cesarean section
this group in which prevention of uterine atony is made by the usual active management of labour syntocinon and methergine during cesarean section</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol + syntocinon and methergine drugs</intervention_name>
    <description>medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and methergine</description>
    <arm_group_label>Active management of labour group</arm_group_label>
    <arm_group_label>Extra medication group</arm_group_label>
    <other_name>DrugsMisoprostol plus syntocinon and metehrgine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntocinon plus methergine drugs</intervention_name>
    <description>medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and methergine</description>
    <arm_group_label>Active management of labour group</arm_group_label>
    <arm_group_label>Extra medication group</arm_group_label>
    <other_name>drugs ( syntocinon and methergine )</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â€¢ All patients included in this research were aged 18-42 years, BMI 20-30,

               -  no medical disorders with pregnancy e.g DM, HTN. All patients were subjected to
                  full history taking, examination.

        Exclusion Criteria:

          -  Exclusion Criteria:

               -  The following patients were excluded ,medical disorders with pregnancy eg. DM
                  with pregnancy, HTN with pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant females</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Alalfy, M.s.c</last_name>
    <role>Study Chair</role>
    <affiliation>Algazeerah hospital -Location (Giza -Egypt )</affiliation>
  </overall_official>
  <overall_official>
    <last_name>yossra Lasheen, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>kasraliny hospital- Aljazeerah hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algazeerah</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Methylergonovine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

